Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis
Brief Summary: This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.


Options:
A: Arm Label: Part A: SAR 100 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 100 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: Placebo qw; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B Cohort 1: Non-selected Doses; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Intervention Type: DRUG; Name: Sarilumab; Assigned to Arm(s): Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Placebo (for sarilumab); Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 150 mg q2w, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
C: Arm Label: DB Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double-blind Placebo | Arm Label: DB adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab | Arm Label: DB Adalimumab/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab | Arm Label: DB Placebo/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab | Arm Label: DB Adalimumab/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Arm Label: DB Placebo/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Intervention Type: BIOLOGICAL; Name: Double-blind adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB adalimumab | Intervention Type: DRUG; Name: Double-blind Placebo; Assigned to Arm(s): DB Placebo, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-label Adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-labelAdalimumabRescue; Assigned to Arm(s): DB Adalimumab/RE OL Adalimumab, DB Placebo/RE OL Adalimumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1

Answer: B